Gå direkt till huvudinnehållet

Toxisk epidermal nekrolys

Senast uppdaterad: Publicerad:
Sakkunnig:

  1. Nirken MH. Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. UpToDate, April 4, 2006. www.uptodate.com. UpToDate  
  2. Roujeau JC, Guillaume JC, Fabre JP et al. Toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 1990; 126: 37-42. PubMed  
  3. Schöpf E, Stuhmer A, Rzany B et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42. PubMed  
  4. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485-95. PubMed  
  5. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6. PubMed  
  6. Roujeau JC, Chosidow O, Saiag P et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58. PubMed  
  7. Revuz J, Penso D, Roujeau JC et al. Toxic epidermal necrolysis: clinicalfindings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5. PubMed  
  8. Letko E, Papaliodis DN, Papaliodis GN et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-36. PubMed  
  9. Cattelan AM, Trevenzoli M, Sasset L et al. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature J Infect 2001; 43: 246-54.
  10. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333: 1600-7. New England Journal of Medicine  
  11. Power WJ, Ghoraishi M, Merayo-Lloves J et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme / Stevens-Johnson syndrome/ toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669-76. PubMed  
  12. McIvor RA, Zaidi J, Peters WJ et al. Acute and chronic respiratory complica-tions of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17: 237-40. PubMed  
  13. Weightman W. Toxic epidermal necrolysis. Australas J Dermatol 1996; 37: 167-75. PubMed  
  14. Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-7. PubMed  
  15. Parsons JM. Management of toxic epidermal necrolysis. Cutis 1985; 36: 305-7. PubMed  
  16. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996; 22: 275-8. PubMed  
  17. Halebian PH, Corder VJ, Madden MR et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12. PubMed  
  18. Lehrer-Bell KA, Kirsner RS, Tallman PG et al. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998; 134: 877-9. PubMed  
  19. Sahar Kohanim S, Palioura S, Saeed HN. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis – A Comprehensive Review and Guide to Therapy. I. Systemic Disease. Ocul Surf. 2016 Jan;14(1):2-19. pmid: 26549248. PubMed  
  20. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53. PubMed  
  21. Arevalo JM, Lorente JA, Gonzalez-Herrada C et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-8. PubMed  
  22. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1993; 128: 357. PubMed  
  23. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991; 25: 778-86. PubMed  
  24. Majumdar S, Mockenhaupt M, Roujeau JC et al. Interventions for toxic epidermal necrolysis. In: The Cochrane Library, Issue 3, 2004. The Cochrane Library  
  25. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005; 136: 205-16. PubMed  
  26. Egan CA, Grant WJ, Morris SE et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458-61. PubMed  
  27. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996; 135: 305-6. PubMed  
  28. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3. PubMed  
  29. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32. PubMed  
  30. Al-Mutairi N, Arun J, Osama NE et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004; 43: 847-51. PubMed  
  31. Tan AW, Thong BY, Yip LW et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005; 32: 1-6. PubMed  
  32. Campione E, Marulli GC, Carrozzo AM et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83: 430-2. PubMed  
  33. Trent JT, Kirsner RS, Romanelli P et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139: 39-43. PubMed  
  34. Barron SJ, Del Vecchio MT, Aronoff SC, et al. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015 Jan;54(1):108-15. PubMed  
  35. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139: 33-6. PubMed  
  36. Brown KM, Silver GM, Halerz M et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25: 81-8. PubMed  
  37. Shortt R, Gomez M, Mittman N et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25: 246-55. PubMed  
  38. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53. PubMed  
  • Tore Särnhult, överläkare, Hudmottagningen, Kungsbacka

Tidigare sakkunniga

  • Terje Johannessen, professor i allmänmedicin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim